On June 4, Hyperliquid Strategies fell 8.29% in pre-market trading, trading at $9.51 USD/share, with trading volume of $959,600.

Within the Biotechnology sector where Hyperliquid Strategies belongs, the overall sector performance is positive. Among individual stocks, AbbVie up 0.93%, Gilead Sciences up 1.43%, Amgen up 2.2%, Vertex Pharmaceuticals up 1.88%, Abivax S.A. up 0.58%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)